Immunosuppressive treatment however is still pivotal to avoid rejection of the transplanted hepatocytes [178] and although preclinical studies seem promising, more data and research, with regard for possible ethical concerns about the use of CRISPR-Cas in humans, is necessary to assess the potential of Cypor deficient hepatocyte transplantation in PKU patients. The gene discussed is POR; the disease is phenylketonuria.